Germany Diabetes Drugs Market Analysis Report [2022-30]

Germany Diabetes Drugs Market Analysis

$ 3999

The Germany diabetes drugs market size was valued at $2.26 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.3% from 2022 to 2030 and will reach $3.16 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Germany diabetes drug market will grow because there is a growing focus on preventive measures to reduce the risk of developing diabetes, including lifestyle changes, which is also driving the demand for diabetes management products and services. The key market players are Boehringer Ingelheim, Sanofi, Boehringer Ingelheim, Eli Lilly and Company and others.

ID: IN10DEPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Chandani Patel

Buy Now

Germany Diabetes Drugs Market Executive Summary

The Germany diabetes drugs market size was valued at $2.26 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.3% from 2022 to 2030 and will reach $3.16 Bn in 2030. Germany has one of the largest economies in the world and is the largest economy in the European Union. The Gross Domestic Product (GDP) of Germany in 2020 was approximately $3.86 trillion USD, according to the World Bank.

Germany is known for having one of the most advanced and well-funded healthcare systems in the world. According to the Organisation for Economic Co-operation and Development (OECD), Germany spent 11.2% of its GDP on healthcare in 2019, which is higher than the OECD average of 8.8%. The German healthcare system is funded through a combination of public and private sources. The majority of healthcare funding in Germany comes from social health insurance contributions paid by employees and employers, with the government also contributing a significant portion of the funding. Private health insurance is also available for those who choose to opt-out of the public insurance system.

Germany, like many other countries, is facing a growing diabetes problem. According to the International Diabetes Federation, approximately 7.5 Mn people in Germany have diabetes, and this number is expected to rise in the coming years. This rise in the prevalence of diabetes has led to a significant impact on the diabetes drugs market in Germany.

As more people in Germany are diagnosed with diabetes, the demand for diabetes drugs has also increased. This has led to a growth in the diabetes drugs market in Germany, with several pharmaceutical companies producing and selling these drugs in the country. At the same time, the cost of diabetes drugs has also become a significant issue in Germany. The German government has been working to control the cost of diabetes drugs, and this has led to increased pressure on pharmaceutical companies to reduce their prices.

In addition, there have been concerns about the safety and effectiveness of some diabetes drugs. This has led to increased regulation of these drugs and closer monitoring of their use in Germany. The demand for these drugs has increased, and there have also been challenges related to cost, safety, and effectiveness that have affected the market.

germany diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

The diabetes market in Germany is driven by several factors, including the increasing prevalence of diabetes, growing awareness of the disease, and advancements in diabetes treatment and management. As more people in Germany are diagnosed with diabetes, the demand for diabetes drugs and devices has also increased, driving the growth of the diabetes market in the country.

In addition, there is a growing focus on preventive measures to reduce the risk of developing diabetes, including lifestyle changes, which is also driving the demand for diabetes management products and services. The German government has been working to address the diabetes epidemic by implementing initiatives aimed at promoting healthy lifestyles and diabetes prevention.

Market Restraints

there are also several restraints that impact the diabetes market in Germany. One of the primary constraints is the cost of diabetes drugs and devices, which can be high and can limit access to diabetes management products and services for some patients. This has led to increased pressure on pharmaceutical companies to reduce their prices and for the government to control healthcare costs.

Moreover, the regulatory environment, which can be complex and stringent. This can impact the development and approval of new diabetes drugs and devices, leading to longer timelines and higher costs for manufacturers.

Competitive Landscape

Key Players

Boehringer Ingelheim
Sanofi
Boehringer Ingelheim
Eli Lilly and Company
AstraZeneca
Johnson & Johnson
Bayer Pharmaceuticals
Novo Nordisk
Merck
Novartis
GlaxoSmithKline

Notable deals

February 2021, Sanofi announced that it had acquired Tidal Therapeutics, a biotech company that is developing mRNA-based treatments for diabetes and other diseases.

July 2021, Merck KGaA and Artios Pharma announced a partnership to develop new cancer and diabetes treatments using DNA damage response (DDR) technologies.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The regulation of diabetes drugs in Germany is the responsibility of the Federal Institute for Drugs and Medical Devices (BfArM), which is a regulatory agency under the authority of the Federal Ministry of Health. The BfArM is responsible for evaluating the safety, efficacy, and quality of drugs before they are approved for use in Germany.

Before a diabetes drug can be approved in Germany, it must undergo a rigorous testing and approval process that includes preclinical and clinical trials. The drug manufacturer must provide extensive data on the safety and efficacy of the drug, including its potential side effects and interactions with other medications. Once a diabetes drug is approved for use in Germany, it is subject to ongoing monitoring and surveillance by the BfArM to ensure that it continues to meet safety and efficacy standards.

In Germany, diabetes drugs are typically reimbursed through the country's statutory health insurance system, which provides coverage to over 85% of the population. The reimbursement system is based on a fixed list of drugs, known as the "positive list," which includes drugs that have been approved for reimbursement by the Federal Joint Committee (G-BA). To be included on the positive list, a diabetes drug must demonstrate a significant benefit over existing treatments, and its cost must be reasonable in relation to its benefit. The G-BA considers a range of factors when making reimbursement decisions, including the drug's clinical effectiveness, its cost, and its impact on patient outcomes.

Once a diabetes drug is approved for reimbursement, it is typically covered by the statutory health insurance system. However, patients may still be responsible for a co-pay or deductible, depending on their specific insurance plan. Some diabetes drugs may also be covered by private health insurance plans, depending on the terms of the individual policy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

Injectable Drugs
- Insulin Based Injectables
- Non-insulin Based Injectables
  - Exenatide (Byetta)
  - Dulaglutide (Trulicity)
  - Semaglutide (Ozempic, Wegovy)
  - Liraglutide (`Saxenda, Victoza)
  - Lixisenatide (Adlyxin)
  - Pramlintide (Symlin)
  - Tirzepatide (Mounjaro)
  - Albiglutide (Tanzeum)
Oral Drugs
- Biguanides - Metformin (Glucophage and Glucophase XR)
- Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
- Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
- Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
- Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
- Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
- Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
- Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
- Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
- Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
- Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.